Who are VLA2001 - adolescent part's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tozinameran 12 Years of age and older, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), BNT162b2 Bivalent (WT/OMI BA.1), BNT162b7 Monovalent (OMI BA.4/BA.5), Lilly Bamlanivimab + Etesevimab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vla2001-adolescent-part.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

VLA2001 - adolescent part — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VLA2001 - adolescent part (VLA2001 - adolescent part) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Infectious Disease.

phase 3 vaccine SARS-CoV-2 spike protein Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

VLA2001 - adolescent part (VLA2001 - adolescent part) — Valneva Austria GmbH. VLA2001 is a COVID-19 vaccine that uses a recombinant, replication-incompetent chimpanzee adenovirus vector to express the SARS-CoV-2 spike protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VLA2001 - adolescent part TARGET	VLA2001 - adolescent part	Valneva Austria GmbH	phase 3	vaccine	SARS-CoV-2 spike protein
Tozinameran 12 Years of age and older	tozinameran-12-years-of-age-and-older	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose	variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)	tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
BNT162b2 Bivalent (WT/OMI BA.1)	bnt162b2-bivalent-wt-omi-ba-1	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b7 Monovalent (OMI BA.4/BA.5)	bnt162b7-monovalent-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
Lilly Bamlanivimab + Etesevimab	Lilly Bamlanivimab + Etesevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VLA2001 - adolescent part — Competitive Intelligence Brief. https://druglandscape.com/ci/vla2001-adolescent-part. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing